The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...
The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while ...
The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...
The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare ...
Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.
The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback